25354-39-6

Basic information

• Product Name: 4,6-dichloro-N-propyl-1,3,5-triazin-2-amine
• CAS NO: 25354-39-6
• Molecular Formula: C₆H₈Cl₂N₄
• Molecular Weight: 207.0605
• Mol File: 25354-39-6.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 368.8°C at 760 mmHg
• Flash Point: 176.8°C
• Density: 1.423g/cm³
• Vapor Pressure: 1.24E-05mmHg at 25°C
• Refractive Index: 1.591
• CAS DataBase Reference: 4,6-dichloro-N-propyl-1,3,5-triazin-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-dichloro-N-propyl-1,3,5-triazin-2-amine(25354-39-6)
• EPA Substance Registry System: 4,6-dichloro-N-propyl-1,3,5-triazin-2-amine(25354-39-6)

Safety Data

• Hazardous Substances Data: 25354-39-6(Hazardous Substances Data)

Upstream product

• 107-10-8 propylamine 
• 108-77-0 1,3,5-trichloro-2,4,6-triazine 

Downstream Products

• 1610533-91-9 N,N'-bis-(4-fluorobenzyl)-N-n-propyl-[1,3,5]triazine-2,4,6-triamine 
• 1522211-02-4 6-chloro-N-(4-fluorophenyl)-N'-n-propyl-[1,3,5]triazine-2,4-diamine 
• 1610533-65-7 O,N-dimethyl-N-[4-(n-propylamino)-6-(prop-2-ynylamino)-[1,3,5]triazin-2-yl]hydroxylamine DL-mandelate 
• 1610534-47-8 N-(3-chloro-2-methylbenzyl)-N'-n-propyl-N-prop-2-ynyl-[1,3,5]triazine-2,4,6-triamine 
• 1610534-46-7 N-(4-fluorophenyl)-N'-propyl-N''-prop-2-ynyl-[1,3,5]triazine-2,4,6-triamine hydrochloride 
• 1610534-45-6 N-(4-fluorophenyl)-N'-propyl-N''-prop-2-ynyl-[1,3,5]triazine-2,4,6-triamine 

Relevant articles and documents

Discovery and Optimization of Triazine Nitrile Inhibitors of Toxoplasma gondii Cathepsin L for the Potential Treatment of Chronic Toxoplasmosis in the CNS

With roughly 2 billion people infected, the neurotropic protozoan Toxoplasma gondii remains one of the most pervasive and infectious parasites. Toxoplasma infection is the second leading cause of death due to foodborne illness in the United States, causes severe disease in immunocompromised patients, and is correlated with several cognitive and neurological disorders. Currently, no therapies exist that are capable of eliminating the persistent infection in the central nervous system (CNS). In this study we report the identification of triazine nitrile inhibitors of Toxoplasma cathepsin L (TgCPL) from a high throughput screen and their subsequent optimization. Through rational design, we improved inhibitor potency to as low as 5 nM, identified pharmacophore features that can be exploited for isoform selectivity (up to 7-fold for TgCPL versus human isoform), and improved metabolic stability (t1/2 > 60 min in mouse liver microsomes) guided by a metabolite ID study. We demonstrated that this class of compounds is capable of crossing the blood-brain barrier in mice (1:1 brain/plasma at 2 h). Importantly, we also show for the first time that treatment of T. gondii bradyzoite cysts in vitro with triazine nitrile inhibitors reduces parasite viability with efficacy equivalent to a TgCPL genetic knockout.

NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME

The present invention includes compositions that are useful in the prevention and/or treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of preventing and/or treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition of the invention. The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition of the invention.

NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES

The present invention includes compositions that are useful in the treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention, The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention.